Author
Listed:
- Chongbiao Huang
(Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer
Senior Ward, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy)
- Na Li
(Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer)
- Zengxun Li
(Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer)
- Antao Chang
(School of Medicine, Nankai University)
- Yanan Chen
(School of Medicine, Nankai University)
- Tiansuo Zhao
(Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer)
- Yang Li
(Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer)
- Xiuchao Wang
(Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer)
- Wei Zhang
(Tianjin Hepingqu Gynaechology and Obstetrics Hospital)
- Zhimin Wang
(Tianjin Hepingqu Gynaechology and Obstetrics Hospital)
- Lin Luo
(Tianjin Hepingqu Gynaechology and Obstetrics Hospital)
- Jingjing Shi
(Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy)
- Shengyu Yang
(Penn State University College of Medicine)
- He Ren
(Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer)
- Jihui Hao
(Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer)
Abstract
Interleukin 35 (IL-35) is a novel member of the IL-12 family, consisting of an EBV-induced gene 3 (EBI3) subunit and a P35 subunit. IL-35 is an immune-suppressive cytokine mainly produced by regulatory T cells. However, the role of IL-35 in cancer metastasis and progression is not well understood. Here we demonstrate that IL-35 is overexpressed in human pancreatic ductal adenocarcinoma (PDAC) tissues, and that IL-35 overexpression is associated with poor prognosis in PDAC patients. IL-35 has critical roles in PDAC cell extravasation and metastasis by facilitating the adhesion to endothelial cells and transendothelial extravasation. Mechanistically, IL-35 promotes ICAM1 overexpression through a GP130-STAT1 signalling pathway, which facilitates endothelial adhesion and transendothelial migration via an ICAM1–fibrinogen–ICAM1 bridge. In an orthotopic xenograft model, IL-35 promotes spontaneous pancreatic cancer metastasis in an ICAM1-dependent manner. Together, our results indicate additional functions of IL-35 in promoting PDAC metastasis through mediating ICAM1 expression.
Suggested Citation
Chongbiao Huang & Na Li & Zengxun Li & Antao Chang & Yanan Chen & Tiansuo Zhao & Yang Li & Xiuchao Wang & Wei Zhang & Zhimin Wang & Lin Luo & Jingjing Shi & Shengyu Yang & He Ren & Jihui Hao, 2017.
"Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression,"
Nature Communications, Nature, vol. 8(1), pages 1-15, April.
Handle:
RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms14035
DOI: 10.1038/ncomms14035
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms14035. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.